Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2023

Open Access 17-09-2023 | Type 2 Diabetes | Case report

Daily dose of metformin caused acute kidney injury with lactic acidosis: a case report

Authors: Maho Ariga, Junichiro Hagita, Midori Soda, Yasuhisa Oida, Hitomi Teramachi, Kiyoyuki Kitaichi

Published in: Journal of Medical Case Reports | Issue 1/2023

Login to get access

Abstract

Background

Metformin-induced lactic acidosis with acute kidney injury is rare but well known. Here we report a case of a Japanese patient taking metformin who experienced severe acute renal failure accompanied with significantly elevated metformin plasma concentrations and signs of lactic acidosis.

Case presentation

A 60-year-old Japanese man with type II diabetes, who was taking metformin (500 mg three times a day) along with several other medications, visited the emergency department with dizziness, malaise, and oliguria. The initial laboratory test results showed elevated levels of serum creatinine and blood urea nitrogen, although his renal function was normal approximately 2 weeks earlier. His lactate level was raised (4.27 mmol/L), and he was diagnosed with lactic acidosis. Considering the low creatinine clearance and elevated urinary albumin/serum creatinine ratio, urinary N-acetyl-β-d-glucosaminidase level, and β2-microglobulin level, the patient was further diagnosed with AKI (in other words, acute tubular necrosis). A renal biopsy performed on day 3 after admission revealed renal tubular epithelium necrosis, supporting this diagnosis. The patient underwent intermittent hemodialysis until he was discharged on day 13. The metformin concentrations on days 3, 5, and 7 were 8.95, 2.58, and 0.16 μg/mL, respectively, which is significantly higher than the maximal steady-state concentration of metformin at the recommended dosage (approximately 1 μg/mL). The calculated pharmacokinetic parameters of metformin suggested poor renal excretion and a low distribution volume at higher metformin levels. Other possible acute kidney injury-causing factors included dehydration, alcohol consumption, and the use of an angiotensin receptor blocker or SGLT2 inhibitor.

Conclusions

This is the first reported case of acute kidney injury possibly caused by high levels of metformin with lactic acidosis in a patient treated with the recommended metformin dose. Thus, the development of metformin-induced acute kidney injury should be considered for patients with several acute kidney injury risk factors who are taking metformin.
Literature
1.
go back to reference Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108:1167–74. CrossRefPubMedPubMedCentral Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108:1167–74. CrossRefPubMedPubMedCentral
2.
go back to reference Suzuki K, Okada H, Yoshida S, Okamoto H, Suzuki A, Suzuki K, et al. Effect of high-flow high-volume-intermittent hemodiafiltration on metformin-associated lactic acidosis with circulatory failure: a case report. J Med Case Rep. 2018;12:280. CrossRefPubMedPubMedCentral Suzuki K, Okada H, Yoshida S, Okamoto H, Suzuki A, Suzuki K, et al. Effect of high-flow high-volume-intermittent hemodiafiltration on metformin-associated lactic acidosis with circulatory failure: a case report. J Med Case Rep. 2018;12:280. CrossRefPubMedPubMedCentral
3.
go back to reference Luft D, Deichsel G, Schmülling RM, Stein W, Eggstein M. Definition of clinically relevant lactic acidosis in patients with internal diseases. Am J Clin Pathol. 1983;80:484–9. CrossRefPubMed Luft D, Deichsel G, Schmülling RM, Stein W, Eggstein M. Definition of clinically relevant lactic acidosis in patients with internal diseases. Am J Clin Pathol. 1983;80:484–9. CrossRefPubMed
4.
go back to reference Calello DP, Liu KD, Wiegand TJ, Roberts DM, Lavergne V, Gosselin S, et al. Extracorporeal treatment for metformin poisoning: systematic review and recommendations from the Extracorporeal Treatments in Poisoning Workgroup. Crit Care Med. 2015;43:1716–30. CrossRefPubMed Calello DP, Liu KD, Wiegand TJ, Roberts DM, Lavergne V, Gosselin S, et al. Extracorporeal treatment for metformin poisoning: systematic review and recommendations from the Extracorporeal Treatments in Poisoning Workgroup. Crit Care Med. 2015;43:1716–30. CrossRefPubMed
5.
go back to reference Abdessadek M, Tadmori AE, Attari AE, Diarra M, Magoul R, Ajdi F, et al. Simple HPLC-UV method for determination of metformin in human plasma and erythrocytes application to therapeutic drug monitoring. Int J Pharm Pharm Sci. 2015;7:35–9. Abdessadek M, Tadmori AE, Attari AE, Diarra M, Magoul R, Ajdi F, et al. Simple HPLC-UV method for determination of metformin in human plasma and erythrocytes application to therapeutic drug monitoring. Int J Pharm Pharm Sci. 2015;7:35–9.
7.
go back to reference Iwai H, Ohno Y, Itoh H, Endo T, Komaki K, Ishii S, et al. Type 2 diabetes mellitus with lactic acidosis and acute renal failure induced by metformin overdose in suicide. J Japan Diab Soc. 2004;47:439–45. Iwai H, Ohno Y, Itoh H, Endo T, Komaki K, Ishii S, et al. Type 2 diabetes mellitus with lactic acidosis and acute renal failure induced by metformin overdose in suicide. J Japan Diab Soc. 2004;47:439–45.
8.
9.
go back to reference Chowdhury W, Lodhi MU, Syed IA, Ahmed U, Miller M, Rahim M. Metformin-induced lactic acidosis: a case study. Cureus. 2018;10: e2152. PubMedPubMedCentral Chowdhury W, Lodhi MU, Syed IA, Ahmed U, Miller M, Rahim M. Metformin-induced lactic acidosis: a case study. Cureus. 2018;10: e2152. PubMedPubMedCentral
10.
go back to reference Rocha A, Almeida M, Santos J, Carvalho A. Metformin in patients with chronic kidney disease: strengths and weaknesses. J Nephrol. 2013;26:55–60. CrossRefPubMed Rocha A, Almeida M, Santos J, Carvalho A. Metformin in patients with chronic kidney disease: strengths and weaknesses. J Nephrol. 2013;26:55–60. CrossRefPubMed
11.
go back to reference Brooks C, Wei Q, Cho SG, Dong Z. Regulation of mitochondrial dynamics in acute kidney injury in cell culture and rodent models. J Clin Invest. 2009;119:1275–85. CrossRefPubMedPubMedCentral Brooks C, Wei Q, Cho SG, Dong Z. Regulation of mitochondrial dynamics in acute kidney injury in cell culture and rodent models. J Clin Invest. 2009;119:1275–85. CrossRefPubMedPubMedCentral
12.
go back to reference Pan Q, Lu X, Zhao C, Liao S, Chen X, Guo F, et al. Metformin: the updated protective property in kidney disease. Aging (Albany NY). 2020;12:8742–59. CrossRefPubMed Pan Q, Lu X, Zhao C, Liao S, Chen X, Guo F, et al. Metformin: the updated protective property in kidney disease. Aging (Albany NY). 2020;12:8742–59. CrossRefPubMed
13.
go back to reference Amini FG, Rafieian-Kopaei M, Nematbakhsh M, Baradaran A, Nasri H. Ameliorative effects of metformin on renal histologic and biochemical alterations of gentamicin-induced renal toxicity in Wistar rats. J Res Med Sci. 2012;17:621–5. PubMedPubMedCentral Amini FG, Rafieian-Kopaei M, Nematbakhsh M, Baradaran A, Nasri H. Ameliorative effects of metformin on renal histologic and biochemical alterations of gentamicin-induced renal toxicity in Wistar rats. J Res Med Sci. 2012;17:621–5. PubMedPubMedCentral
14.
go back to reference McDaniel BL, Bentley ML. The role of medications and their management in acute kidney injury. Integr Pharm Res Pract. 2015;4:21–9. PubMedPubMedCentral McDaniel BL, Bentley ML. The role of medications and their management in acute kidney injury. Integr Pharm Res Pract. 2015;4:21–9. PubMedPubMedCentral
15.
go back to reference Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, et al. Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharmacol. 1995;35:1094–102. CrossRefPubMed Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, et al. Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharmacol. 1995;35:1094–102. CrossRefPubMed
16.
go back to reference Kuan IHS, Wilson LC, Leishman JC, Cosgrove S, Walker RJ, Putt TL, et al. Metformin doses to ensure efficacy and safety in patients with reduced kidney function. PLoS ONE. 2021;16: e0246247. CrossRefPubMedPubMedCentral Kuan IHS, Wilson LC, Leishman JC, Cosgrove S, Walker RJ, Putt TL, et al. Metformin doses to ensure efficacy and safety in patients with reduced kidney function. PLoS ONE. 2021;16: e0246247. CrossRefPubMedPubMedCentral
17.
go back to reference Choi YH, Lee I, Lee MG. Effects of water deprivation on the pharmacokinetics of metformin in rats. Biopharm Drug Dispos. 2007;28:373–83. CrossRefPubMed Choi YH, Lee I, Lee MG. Effects of water deprivation on the pharmacokinetics of metformin in rats. Biopharm Drug Dispos. 2007;28:373–83. CrossRefPubMed
18.
go back to reference Tsuboi N, Yoshida H, Shibamura K, Hikita M, Tomonari H, Kuriyama S, et al. Acute renal failure after binge drinking of alcohol and nonsteroidal antiinflammatory drug ingestion. Intern Med. 1997;36:102–6. CrossRefPubMed Tsuboi N, Yoshida H, Shibamura K, Hikita M, Tomonari H, Kuriyama S, et al. Acute renal failure after binge drinking of alcohol and nonsteroidal antiinflammatory drug ingestion. Intern Med. 1997;36:102–6. CrossRefPubMed
19.
go back to reference Hulisz DT, Bonfiglio MF, Murray RD. Metformin-associated lactic acidosis. J Am Board Fam Pract. 1998;11:233–6. CrossRefPubMed Hulisz DT, Bonfiglio MF, Murray RD. Metformin-associated lactic acidosis. J Am Board Fam Pract. 1998;11:233–6. CrossRefPubMed
20.
go back to reference Gudmundsdottir H, Aksnes H, Heldal K, Krogh A, Froyshov S, Rudberg N, et al. Metformin and antihypertensive therapy with drugs blocking the renin angiotensin system, a cause of concern? Clin Nephrol. 2006;66:380–5. CrossRefPubMed Gudmundsdottir H, Aksnes H, Heldal K, Krogh A, Froyshov S, Rudberg N, et al. Metformin and antihypertensive therapy with drugs blocking the renin angiotensin system, a cause of concern? Clin Nephrol. 2006;66:380–5. CrossRefPubMed
21.
go back to reference Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, Moriyama Y. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci U S A. 2005;102:17923–8. CrossRefPubMedPubMedCentral Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, Moriyama Y. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci U S A. 2005;102:17923–8. CrossRefPubMedPubMedCentral
22.
go back to reference Masuda S, Terada T, Yonezawa A, Tanihara Y, Kishimoto K, Katsura T, Ogawa O, Inui K. Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol. 2006;17:2127–35. CrossRefPubMed Masuda S, Terada T, Yonezawa A, Tanihara Y, Kishimoto K, Katsura T, Ogawa O, Inui K. Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol. 2006;17:2127–35. CrossRefPubMed
23.
go back to reference Stocker SL, Morrissey KM, Yee SW, Castro RA, Xu L, Dahlin A, et al. The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther. 2013;93:186–94. CrossRefPubMed Stocker SL, Morrissey KM, Yee SW, Castro RA, Xu L, Dahlin A, et al. The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther. 2013;93:186–94. CrossRefPubMed
Metadata
Title
Daily dose of metformin caused acute kidney injury with lactic acidosis: a case report
Authors
Maho Ariga
Junichiro Hagita
Midori Soda
Yasuhisa Oida
Hitomi Teramachi
Kiyoyuki Kitaichi
Publication date
17-09-2023
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2023
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/s13256-023-04136-0

Other articles of this Issue 1/2023

Journal of Medical Case Reports 1/2023 Go to the issue

Test your knowledge with Case-Based Clinical Insights

Oncology and Hematology Cases

A 28-year-old male patient (188 cm, 72 kg) presents to the central emergency department with dorsal pain after returning from a trip to East Asia. He reports feeling a bit tired and listless without classic signs of infection. In the clinical examination, apart from an approximately fist-sized, deeply situated, sturdy and non-displaceable bulging of the abdominal wall sinistrally paraumbilically, a slight enlargement of the left testis with pain upon palpation is noticeable. What is your first suspicion, and what are your first diagnostic steps?

The 46-year-old male patient has been showing various signs of inflammation for 6–8 weeks: Sore throat, canker sores, joint pain and febrile rhinitis. There is an unintended weight loss of 2–3 kg. Physical examination reveals findings that are inconspicuous for the patient’s age. How do you proceed now?

A 76-year-old, overweight female patient with anaemia and type II diabetes noted by her family doctor presents with fatigue, forgetfulness and yellowish pallor in a neglected state. Moreover, she shows an increasingly unsteady gait. How do you proceed?

A 56-year-old man presents with concentration problems, dorsal pain, fatigue and a marked increase in urination. His family history is positive for bronchial carcinoma. Physical examination reveals tenderness upon percussion in the lumbar spine. How do you proceed?

Navigating the Treatment of Renal Cell Carcinoma

Insights on the Current Treatment Landscape and Managing Patient Health

In recent years, tremendous efforts have been made in the medical treatment of metastatic renal cell carcinoma (mRCC), with Immune-Oncological combinations standing as the current standard of care in the first-line setting of mRCC. 

In these podcasts, expert authors discuss the current treatment landscape for these new therapies and discuss what should be taken into account when choosing the most appropriate treatment for their patients so as to balance oncological outcomes, adverse events and quality of life.

Supported by an unrestricted educational grant from Eisai Europe Limited.

Listen now